Custom CRISPR Multiplex sgRNA Vectors
abm’s Custom CRISPR Multiplex sgRNA system allows for optimal expression of multiple sgRNAs from alternating U6 and H1 RNA pol III promoters on a single lentiviral vector (for other vector options please inquire). This allows for expression of multiple sgRNAs targeting a single gene or multiple sgRNAs targeting multiple different genes. sgRNAs may be designed for use with any Cas9 variant, which is expressed from a separate vector. Together, the Multiplex sgRNA Vectors expand the CRISPR toolkit allowing for highly diverse gene editing applications. To get started on your custom project, simply click the Inquire button below.
- Gene activation using dCas9-SAM
- Gene repression using dCas9-KRAB
- Epigenetic gene activation using dCas9-TET1CD
- Epigenetic gene repression using dCas9-DNMT3A
- Gene Knockout using spCas9 or saCas9
|sgRNA Service (for spCas9)||No. of sgRNAs||Quantity||Cat. No.||Price|
|Custom CRISPR Dual sgRNA Lentivector (for spCas9)||2||1.0 ug||C420||$395.00|
|Custom CRISPR Triple sgRNA Lentivector (for spCas9)||3||1.0 ug||C421||$595.00|
|Custom CRISPR Quad sgRNA Lentivector (for spCas9)||4||1.0 ug||C422||$795.00|
|Custom CRISPR Multiplex sgRNA Lentivector (for spCas9)||>4||1.0 ug||C423||Inquire|
|sgRNA Service (for saCas9)||No. of sgRNAs||Quantity||Cat. No.||Price|
|Custom CRISPR Dual sgRNA Lentivector (for saCas9)||2||1.0 ug||C511||$395.00|
|Custom CRISPR Triple sgRNA Lentivector (for saCas9)||3||1.0 ug||C512||$595.00|
|Custom CRISPR Quad sgRNA Lentivector (for saCas9)||4||1.0 ug||C513||$795.00|
|Custom CRISPR Multiplex sgRNA Lentivector (for saCas9)||>4||1.0 ug||C514||Inquire|
|Packaging Options||Unit||Cat. No.||Price|
|High Titer Custom Recombinant Lentivirus (107 IU/ml)||4 x 500 ul||LV002-a||$395.00|
|High Titer Custom Recombinant Lentivirus (108 IU/ml)||4 x 250 ul||LV002-b||$595.00|
|High Titer Custom Recombinant Lentivirus (109 IU/ml)||10 x 100 ul||LV002-c||$959.00|
|High Titer Custom Recombinant Lentivirus (1010 IU/ml)||10 x 100 ul||LV002-d||$1395.00|
|Lentivirus Custom Aliquotting||Up to 10 Vials||C507||$50.00|
|What promoter(s) do your sgRNA and All-in-One lentivectors have?|
sgRNAs are expressed from the U6 promoter and All-in-One lentivectors and lentiviruses express Cas9 from the SFFV promoter.
|What is the approximate time frame to generate CRISPR lentiviral constructs?|
The typical lead time is around 1-3 weeks for CRISPR lentivectors and 4-6 weeks for lentiviruses. Please inquire for a more accurate lead time.
|How should I store my lentivirus?|
Aliquots should be made for the lentivirus and stored at -70 degrees Celsius.
|If a high-titer custom lentivirus was ordered, do you do the lentiviral titration after a freeze-thaw or straight after production before the freeze-down step?|
We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.
|Which virus has your lentivirus expression system been derived from? Is it HIV?|
Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.
|How do you verify the titer?|
We use our LV900 series - qPCR Lentivirus Titration(Titer) Kit. This kit quantifies a proprietary region of the lentiviral 5’-LTR.
|What is the packaging capacity for Lentivirus?|
The maximum insert size is <9 kb between the 5'LTR to 3'LTR.
|01||Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371|
|02||Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338|
|03||Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359|